ADCs, CDK4/6 Inhibitors, and SERDs Broaden HR+ and Triple-Negative Breast Cancer Treatment Paradigms
August 4th 2023Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease.
Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts
August 3rd 2023Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.
T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup
August 3rd 2023Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.
Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB
July 27th 2023Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective
July 27th 2023Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.
Use of ADCs in the Second-Line Treatment of HER2+ mBC
July 20th 2023Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC
July 20th 2023Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.
Data Updates and Ongoing Trials in the HER2+ Adjuvant Space
July 13th 2023Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.
Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen
July 6th 2023Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.
How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?
July 6th 2023Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
June 29th 2023Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Multidisciplinary Strategies in RCC Management: Future Directions in Care
Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.
Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence
Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.
Combination IO TKI Therapy in Patients With Metastatic Renal Cell Carcinoma
Focused discussion on combination IO-TKI therapy and its role as first-line therapy in patients diagnosed with metastatic renal cell carcinoma.
Scenario 2: A 59-Year-Old Man With Favorable Risk Metastatic RCC
Moving on to the second patient scenario of renal cell carcinoma, panelists reflect on the treatment pathway for favorable risk metastatic disease.